Reversible osimertinib‑associated heart failure mimicking cancer recurrence in EGFR ‑mutated non‑small cell lung cancer after pneumonectomy: A case report
. Osimertinib is a third‑generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor widely used in patients with EGFR mutation‑positive non‑small cell lung cancer (NSCLC). Although generally well tolerated, clinically notable cardiovascular toxicities, including heart failure, have been recognized. Th...